Excerpts

PFS was similar in both treatment arms, whereas OS showed a trend in favor of the panitumumab-containing arm (hazard ratio for death, 0.67; 95% CI, 0.41 to 1.11; p = 0.12).

Ogg1-KO mice fed LFD showed a trend toward lower lean body mass ( p = 0.1218, Supplementary Figure S1B ) and higher fat mass ( p = 0.1231, Supplementary Figure S1C ) compared to WT/LFD mice although neither difference was significant.

In multivariable Cox regression analysis adjusted for age, tumor size, lymph node status, histologic grade, and Ki-67, high AMPKβ protein expression was significantly associated with poorer DFS (HR, 2.932; 95% CI, 1.009–8.519; p = 0.048), while only a nonsignificant trend toward poorer DDFS was observed (HR, 2.645; 95% CI, 0.765–9.139; p = 0.124) in patients with early TNBC ( Supplementary Table S2 ).

Specifically, CA3 was higher in the cold–wet (↓CI/↑RAP) group than in warm–dry (↑CI/↓RAP; p = 0.034) and showed a trend toward being higher than warm–wet (↑CI/↑RAP; p = 0.128; Figure 2 a).

Although the high APOC2 expression group showed a trend toward lower survival compared to the low expression group, this difference was not statistically significant (log-rank test, p = 0.13) ( Figure 4 B).

In A2780 cell line statistically significant decreased expression of PTPRK was observed after 24 h, 48 h and 72 h incubation ( p < 0.05), with the exception of 10 ng/mL after 48 h incubation where downregulation was close to significance ( p = 0.13) ( Figure 4 B). 2.5.

Since these SNPs were close to significance, the haplotype was considered, but even combined together, they were not correlated with the grade of side effect ( p = 0.13).

Using multicolor FACS analysis, we showed that there is a positive trend of correlation (correlation coefficient = 0.80, p = 0.13 on cycle 1 day 8; correlation coefficient = 0.50, p = 0.45 on cycle 1 day 15) between the early granulocyte (CD45 + CD66b + ) population relative to progression free survival (PFS) (months) over cycle 1 of treatment ( Supplementary Figure S2c ).

A concentration of 50 μM showed a trend towards increased LDH release, although the difference to untreated control cells remained statistically non-significant ( p = 0.13).

Lung weight showed a decreasing trend in the DOXO-only group compared to the control group ( p = 0.13).

However, we did find an almost significant difference for TrpN, with an increase in children with moderate impairment (389.13 vs. 528.14; p = 0.13).

In a different randomized trial in the adjuvant setting, AE37 and GP2, two other HER2 derived peptide vaccines were investigated in a four-arm, prospective, randomized, single-blinded, multi-center phase II trial; the AE37 arm showed no difference in DFS overall; however, subgroup analyses showed a trend towards benefit in advanced stage ( p = 0.132, HR 0.573 CI 0.275–1.193), HER2 under-expression ( p = 0.181, HR 0.756 CI 0.499–1.145), and triple-negative breast cancer ( p = 0.266, HR 0.443 CI 0.114–1.717).

This correlation trend was also observed for the functional BCL-2 BH3 profile and CHOP response, in which a high BAD response showed a trend towards high CHOP IC 50 values ( r = 0.595; p = 0.1323) ( Figure 3 E).

Also, LV mass showed a trend towards an increase in the DEB1 subgroup compared to DEB2 ( p = 0.134, Figure 1 E).

Socioeconomic and social factors (k = 4) [ 79 , 80 , 81 , 82 ] showed a positive trend ( p = 0.139), but no statistically significant association was observed.

Of interest, after 24 h the four individuals with highest LLS showed a trend towards lower IL-10 plasma concentrations (lowest LLS 4.02 (2.18–7.13) pg/mL vs. highest LLS 1.80 (0.91–2.48) pg/mL, p = 0.14). 2.5.2.

No significant difference in toughness was evidenced between the two groups of animals, even if the data were close to the limit of significance ( Figure 2 E; −33%, p = 0.14).

The low dosage (Low) group showed a trend of inhibitory effect on paw swelling when compared with the model group ( p = 0.14), as shown in Figure 1 B,C.

The area under the curve measurements for these conditions show a nonsignificant trend toward increased migration ( Figure 5 B; p = 0.144).

At day 10, the difference in collagen III expression was nearly significant ( p = 0.145), with FBs expressing 31.33 ± 1.62%, cocultures 40.60 ± 2.86%, and ECs 44.92 ± 7.92%.

Moreover, the TGF-β1-TG mice showed a trend toward higher fibronectin (FBN) mRNA expression in the ventricular tissue compared to the WT animals ( p = 0.15) ( Figure 2 D).

SLC16A3 also showed a trend toward an inverse correlation with brain pH in controls (r = −0.49, p = 0.15) and a significant inverse correlation in SCZ (r = −0.65, p = 0.04), but not in BD (r = +0.49, p = 0.15).

Non-HSCT GATA2-deficient patients showed a trend toward increased relative abundance of Proteobacteria compared with HD and post-HSCT patients ( p = 0.15 and p = 0.73, respectively; Figure 2 A,B).

The expression level of precursor SREBP-1c protein was also lower, but showing only a tendency towards significance ( p = 0.15). 3.

Mocetinostat showed a decreasing trend in the level of STAT3 protein in LV of treated CHF compared to untreated CHF animals ( p = 0.15).